145 related articles for article (PubMed ID: 21709445)
1. The Myc-ARF-Egr1 pathway: unleashing the apoptotic power of c-Myc.
Boone DN; Hann SR
Cell Cycle; 2011 Jul; 10(13):2043-4. PubMed ID: 21709445
[No Abstract] [Full Text] [Related]
2. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.
Boone DN; Qi Y; Li Z; Hann SR
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):632-7. PubMed ID: 21187408
[TBL] [Abstract][Full Text] [Related]
3. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
Wirth M; Stojanovic N; Christian J; Paul MC; Stauber RH; Schmid RM; Häcker G; Krämer OH; Saur D; Schneider G
Nucleic Acids Res; 2014; 42(16):10433-47. PubMed ID: 25147211
[TBL] [Abstract][Full Text] [Related]
4. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity.
Zhang Q; Spears E; Boone DN; Li Z; Gregory MA; Hann SR
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):978-83. PubMed ID: 23277542
[TBL] [Abstract][Full Text] [Related]
5. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway.
Klefstrom J; Verschuren EW; Evan G
J Biol Chem; 2002 Nov; 277(45):43224-32. PubMed ID: 12202489
[TBL] [Abstract][Full Text] [Related]
6. 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
Yun S; Vincelette ND; Knorr KL; Almada LL; Schneider PA; Peterson KL; Flatten KS; Dai H; Pratz KW; Hess AD; Smith BD; Karp JE; Hendrickson AE; Fernandez-Zapico ME; Kaufmann SH
Blood; 2016 Jun; 127(22):2711-22. PubMed ID: 26917778
[TBL] [Abstract][Full Text] [Related]
7. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.
Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA
Cancer Res; 2012 Nov; 72(22):6065-75. PubMed ID: 22986743
[TBL] [Abstract][Full Text] [Related]
8. Identification of AKT-regulated genes in inducible MERAkt cells.
Kuhn I; Bartholdi MF; Salamon H; Feldman RI; Roth RA; Johnson PH
Physiol Genomics; 2001 Dec; 7(2):105-14. PubMed ID: 11773597
[TBL] [Abstract][Full Text] [Related]
9. PTEN regulation by Akt-EGR1-ARF-PTEN axis.
Yu J; Zhang SS; Saito K; Williams S; Arimura Y; Ma Y; Ke Y; Baron V; Mercola D; Feng GS; Adamson E; Mustelin T
EMBO J; 2009 Jan; 28(1):21-33. PubMed ID: 19057511
[TBL] [Abstract][Full Text] [Related]
10. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
[TBL] [Abstract][Full Text] [Related]
12. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
13. p19ARF directly and differentially controls the functions of c-Myc independently of p53.
Qi Y; Gregory MA; Li Z; Brousal JP; West K; Hann SR
Nature; 2004 Oct; 431(7009):712-7. PubMed ID: 15361884
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms.
Qi CF; Kim YS; Xiang S; Abdullaev Z; Torrey TA; Janz S; Kovalchuk AL; Sun J; Chen D; Cho WC; Gu W; Morse Iii HC
Int J Mol Sci; 2012; 13(5):6204-6219. PubMed ID: 22754359
[TBL] [Abstract][Full Text] [Related]
15. The ARF tumor suppressor: keeping Myc on a leash.
Gregory MA; Qi Y; Hann SR
Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
[TBL] [Abstract][Full Text] [Related]
16. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
17. E2F1 and c-Myc in cell growth and death.
Matsumura I; Tanaka H; Kanakura Y
Cell Cycle; 2003; 2(4):333-8. PubMed ID: 12851485
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.
Valsesia-Wittmann S; Magdeleine M; Dupasquier S; Garin E; Jallas AC; Combaret V; Krause A; Leissner P; Puisieux A
Cancer Cell; 2004 Dec; 6(6):625-30. PubMed ID: 15607966
[TBL] [Abstract][Full Text] [Related]
19. c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade.
Desbiens KM; Deschesnes RG; Labrie MM; Desfossés Y; Lambert H; Landry J; Bellmann K
Biochem J; 2003 Jun; 372(Pt 2):631-41. PubMed ID: 12646044
[TBL] [Abstract][Full Text] [Related]
20. Bax is a transcriptional target and mediator of c-myc-induced apoptosis.
Mitchell KO; Ricci MS; Miyashita T; Dicker DT; Jin Z; Reed JC; El-Deiry WS
Cancer Res; 2000 Nov; 60(22):6318-25. PubMed ID: 11103792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
